Lv21
136 积分 2025-03-06 加入
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
20天前
已完结
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial
22天前
已完结
OP0295 RITUXIMAB VERSUS TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: 52-WEEK OUTCOMES OF A STRATIFIED BIOPSY-DRIVEN, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL
22天前
已完结
ABS0514 EFFICACY AND SAFETY OF TOCILIZUMAB IN SYSTEMIC SCLEROSIS: A RETROSPECTIVE, MONOCENTRIC STUDY
1个月前
已关闭
POS0652 SAFETY AND EFFICACY OF TOCILIZUMAB IN SYSTEMIC SCLEROSIS: A MULTICENTER FRENCH-ITALIAN RETROSPECTIVE STUDY
1个月前
已关闭
P153 Rituximab and tocilizumab and their effect on lung disease progression in scleroderma: a retrospective cohort study at a single centre
1个月前
已关闭
P153 Rituximab and tocilizumab and their effect on lung disease progression in scleroderma: a retrospective cohort study at a single centre
1个月前
已关闭
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
1个月前
已完结
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis
1个月前
已关闭
皖公网安备34019202002308
